Genmab — Juni 2020
-
-
Isa+CyBorD i 1. linje er i fase 1, så der er nogen tid endnu. https://www.clinicaltrials.gov/ct2/show/NCT02513186?term=isatuximab+mm&draw=2&rank=2
-
Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference https://ir.genmab.com/news-releases/news-release-details/genmab-participate-virtual-fireside-chat-goldman-sachs-41st
-
kl. 21 i dag
-
korrektion kl 21 den 11. juni
-
hhmm Antony Pagano i stedet for JvdW
-
this SY-1425 combi for MDS seems fully recruited, didn't thinke we would hear from that again, primary completion date this month, maybe we can get some data at some point https://clinicaltrials.gov/ct2/history/NCT02807558?A=14&B=15&C=merged#StudyPageTop
-
Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma
Company Announcement Subcutaneous fixed-dosed formulation of DARZALEX® (daratumumab) approved in Europe for the treatment of adult patients with multiple...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind